Next-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Leptomeningeal Carcinomatosis Review of 2 CasesGrimsrud, Kate W., MD; Mrugala, Maciej M., MD, PhDThe Neurologist: March 2019 - Volume 24 - Issue 2 - p 59–61 doi: 10.1097/NRL.0000000000000220 Case Report/Case Series Buy SDC Abstract Author InformationAuthors Article MetricsMetrics Introduction: Epidermal growth factor receptor (EGFR) mutation status is strongly correlated with leptomeningeal carcinomatosis in non–small cell lung cancer. Historically, patients were treated with radiotherapy, intrathecal chemotherapy or first-generation EGFR tyrosine kinase inhibitors (TKIs); however, most would eventually develop resistance and disease progression. Therefore, recent interest has sparked in investigating next-generation EGFR-TKI monotherapy. Case reports: We describe 2 patients with non–small cell lung adenocarcinoma who later presented with leptomeningeal disease, treated with next-generation EGFR-TKI monotherapy, independent of whole-brain radiotherapy, with favorable response and outcome. Conclusions: The next-generation EGFR-TKIs may have improved success in treatment of leptomeningeal metastases in non–small cell lung adenocarcinoma when compared with the first-generation and second-generation EGFR-TKIs. Next-generation EGFR-TKI monotherapy should be considered in select patients with leptomeningeal metastases from lung adenocarcinoma. More research is needed to review this potential therapeutic option, especially for use as first-line therapy. Department of Neurology, Mayo Clinic, Scottsdale, AZ The authors declare no conflict of interest. Correspondence to: Kate W. Grimsrud, MD, 13400 E. Shea Blvd., Scottsdale, AZ 85259. E-mail: email@example.com. Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.